Explore a selection of our essential drug information below, or:
Overview
- DrugBank ID
- DB08991
- Type
- Small Molecule
- Clinical Trials
- Phase 0
- 0
- Phase 1
- 0
- Phase 2
- 0
- Phase 3
- 0
- Phase 4
- 0
Identification
- Generic Name
- Epirizole
- DrugBank Accession Number
- DB08991
- Background
Epirizole is an oral nonsteroidal anti-inflammatory drug (NSAID) used for muscle and joint pain.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Epirizole (DB08991)
- Weight
- Average: 234.2545
Monoisotopic: 234.111675712 - Chemical Formula
- C11H14N4O2
- Synonyms
- 4-methoxy-2-(5-methoxy-3-methylpyrazol-1-yl)-6-methylpyrimidine
- Epirizol
- Epirizole
- Epirizolum
- Mepirizol
- Methopyrimazole
- Polihexanid
- External IDs
- DA 398
- DA-398
- Knoll 533
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Epirizole may decrease the excretion rate of Abacavir which could result in a higher serum level. Abciximab The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Abciximab. Acebutolol Epirizole may decrease the antihypertensive activities of Acebutolol. Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Epirizole. Acemetacin The risk or severity of adverse effects can be increased when Epirizole is combined with Acemetacin. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Epirizole hydrochloride 138HY1BQ0T Not Available YJVOCLSBUGKSCI-UHFFFAOYSA-N - International/Other Brands
- Karmarte (Toho) / Mebron (Daiichi Sankyo)
Categories
- Drug Categories
- Agents causing hyperkalemia
- Agents that produce hypertension
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antirheumatic Agents
- Nephrotoxic agents
- Non COX-2 selective NSAIDS
- Peripheral Nervous System Agents
- Pyrazoles
- Pyrimidines
- Sensory System Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alkyl aryl ethers. These are organic compounds containing the alkyl aryl ether functional group with the generic formula R-O-R' , where R is an alkyl group and R' is an aryl group.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Ethers
- Direct Parent
- Alkyl aryl ethers
- Alternative Parents
- Pyrimidines and pyrimidine derivatives / Pyrazoles / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives
- Substituents
- Alkyl aryl ether / Aromatic heteromonocyclic compound / Azacycle / Azole / Heteroaromatic compound / Hydrocarbon derivative / Organic nitrogen compound / Organoheterocyclic compound / Organonitrogen compound / Organopnictogen compound
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 3B46O2FH8I
- CAS number
- 18694-40-1
- InChI Key
- RHAXSHUQNIEUEY-UHFFFAOYSA-N
- InChI
- InChI=1S/C11H14N4O2/c1-7-5-9(16-3)13-11(12-7)15-10(17-4)6-8(2)14-15/h5-6H,1-4H3
- IUPAC Name
- 4-methoxy-2-(5-methoxy-3-methyl-1H-pyrazol-1-yl)-6-methylpyrimidine
- SMILES
- COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1
References
- Synthesis Reference
South African Patent Application 67/4936; January 19, 1968; assigned to Daiichi Seiyaku Company Limited, Japan.
- General References
- Not Available
- External Links
- KEGG Drug
- D01394
- PubChem Compound
- 3242
- PubChem Substance
- 310264952
- ChemSpider
- 3129
- ChEBI
- 31545
- ChEMBL
- CHEMBL1411693
- ZINC
- ZINC000000057412
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Epirizole
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 90-92 South African Patent Application 67/4936; January 19, 1968; assigned to Daiichi Seiyaku Company Limited, Japan. - Predicted Properties
Property Value Source Water Solubility 1.13 mg/mL ALOGPS logP 1.56 ALOGPS logP 1.45 Chemaxon logS -2.3 ALOGPS pKa (Strongest Basic) 1.96 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 62.06 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 62.71 m3·mol-1 Chemaxon Polarizability 24.79 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 168.6579418 predictedDarkChem Lite v0.1.0 [M-H]- 152.5788 predictedDeepCCS 1.0 (2019) [M+H]+ 169.2157418 predictedDarkChem Lite v0.1.0 [M+H]+ 154.93684 predictedDeepCCS 1.0 (2019) [M+Na]+ 168.3804418 predictedDarkChem Lite v0.1.0 [M+Na]+ 161.03008 predictedDeepCCS 1.0 (2019)
Drug created at June 10, 2014 23:13 / Updated at February 21, 2021 18:52